6 news items
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
VIR
13 May 24
the potential to stimulate an effective immune response and has direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
VIR
7 May 24
, it signifies their response to recent developments related to Vir Biotechnology. This offers insight into analysts' perspectives on the current state
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
ANTX
VBIV
VIR
22 Mar 24
trigger a potent and specific immune response in chronic Hepatitis B (CHB) patients and linking that response to improved clinical outcomes
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
VIR
15 Mar 24
Key Insights:
Action Taken: In response to dynamic market conditions and company performance
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
VIR
5 Mar 24
virus-targeting small interfering ribonucleic acid (siRNA) that Vir believes has the potential to stimulate an immune response and have direct antiviral
qmj ukcw8d6jo43ycobir01w70h1i1oxx3k6v1hh3rgqazeu
VIR
22 Feb 24
.
The data demonstrated an approximately three-fold higher response rate when adding tobevibart to a regimen of elebsiran with or without
- Prev
- 1
- Next